CTRI/2019/04/018403进行中（未招募）1 期
An Open Label Clinical trial to assess the Safety and Efficacy of CV-HFD01 tablets as Adjuvant Therapy in patients with Type 2 DM. - CV-HFD01
Climic Health Pvt Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients between 30-60 (both inclusive) age, both sex.
- •2. Patients receiving Oral Hypoglycemic Agents as ongoing treatment for Type 2 DM .
- •3. Hemoglobin A1c (HbA1c) >6.5% and <10% (both inclusive)
- •4. Fasting Plasma Glucose (FPG) >130 mg/dL and < 250 mg/dL (both inclusive)
排除标准
- •1. Type 1 diabetes.
- •2. Under Insulin treatment.
- •3. Patients with concurrent serious Hepatic Dysfunction (defined asAST and/or ALT >3 times of the upper normal limit) or RenalDysfunction (defined as S. creatinine >1.4 mg/dl), uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or otherconcurrent severe disease.
- •4. Women who are pregnant or lactating
- •5. Smokers/Alcoholics and/or drug abusers
- •6. Patient with poorly controlled Hypertension
- •7. Patients with evidence of malignancy
- •8. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro- Endocrinal disorders, etc.)
研究者
相似试验
进行中（未招募）
1 期
A Clinical trial of CV-HFT01 tablets as Adjuvant Therapy in patients with hypothyroidismCTRI/2019/04/018564Climic Health Pvt Ltd
已完成
1 期
This is phase one study with healthy adult participants to be enrolled to receive study product to check the safety and tolerability of liquid rotavirus vaccine in healthy adultsCTRI/2015/11/006384Serum Institute of India Limited20
已完成
不适用
Open-label clinical trial to evaluate the safety and efficacy of the investigational devices in total hip arthroplasty.Patients with hip joint disease caused by hip osteoarthritis and others.JPRN-UMIN000012433KYOCERA Medical Corporation20
进行中（未招募）
1 期
Clinical study to find out whether methylene blue injection is safe and effective in the treatment of a blood disorder (methemoglobinemia) resulting from exposure to toxic agents (drugs or environmental poisons)Acquired methemoglobinemiaMedDRA version: 20.0Level: LLTClassification code 10054290Term: Acquired methemoglobinemiaSystem Organ Class: 100000004851EUCTR2017-000290-37-GBProvepharm SAS10
进行中（未招募）
1 期
Clinical study to find out whether methylene blue injection is safe and effective in the treatment of a blood disorder (methemoglobinemia) resulting from exposure to toxic agents (drugs or environmental poisons)Acquired methemoglobinemiaMedDRA version: 20.0Level: LLTClassification code 10054290Term: Acquired methemoglobinemiaSystem Organ Class: 100000012871EUCTR2017-000290-37-FRProvepharm SAS10